Latest Asx News

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Magnis Energy Technologies reports ongoing progress on its Nachu Graphite Project while grappling with Imperium3’s bankruptcy and a prolonged ASX trading suspension.

Peppermint Innovation Ltd has bolstered its financial position with a $3 million convertible note while navigating a challenging quarter marked by cybersecurity disruptions and strategic divestments. The company is poised for recovery with new advisory expertise and enhanced payment integrations in the Philippines.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Panther Metals reports standout high-grade gold intercepts at its Laverton Gold Project despite flooding setbacks, while advancing its Coglia Nickel-Cobalt Project towards a Pre-Feasibility Study.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Lithium Plus Minerals reports promising pegmatite intersections at its Liana Prospect and maintains a solid cash position of A$4.08 million, setting the stage for expanded exploration in 2025.

Dundas Minerals has identified a significant 1km gold mineralisation trend at its Rockland project and completed a key drilling program at Baden-Powell, with assay results expected soon.

Oldfields Holdings Limited reports a robust second quarter for FY2025, highlighting successful strategic realignment and improved financial performance despite ongoing transition costs.

Larvotto Resources has reported robust progress at its Hillgrove Antimony-Gold Project, highlighted by exceptional drilling results and a successful $30 million capital raise, positioning the company for production by late 2025.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Great Northern Minerals Limited reports significant progress in the sale of its Golden Ant Mining project, with a $1.3 million Earn-In Stage payment expected soon, alongside notable board changes and strategic project reviews.